4.08

72.53% -10.77

Pre-market: 3.95 -0.13 -3.19%

Elicio Therapeutics Inc (ELTX)

Overview News Price History Discussions Forecast

Elicio Therapeutics Inc stock is traded at $4.08, with a volume of 8.40M. It is down -72.53% in the last 24 hours and down -61.62% over the past month. Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Previous Close:

$14.85

Open:

$4.785

24h Volume:

8.40M

Relative Volume:

32.83

Market Cap:

$77.87M

Revenue:

Net Income/Loss:

$-40.19M

P/E Ratio:

-1.7403

EPS:

-2.3444

Net Cash Flow:

$-38.49M

1W Performance:

-69.89%

1M Performance:

-61.62%

6M Performance:

-52.11%

1Y Performance:

-46.32%

1-Day Range:

$3.62

$4.80

1-Week Range:

$3.62

$16.00

52-Week Range:

$3.62

$16.00

Elicio Therapeutics Inc Stock (ELTX) Company Profile

Name

Elicio Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(857) 209-0050

Address

451 D STREET, 5TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ELTX's Discussions on Twitter

Compare ELTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELTX Elicio Therapeutics Inc	4.08	77.87M	0	-40.19M	-38.49M	-2.3444
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Ladenburg Thalmann	Buy
Mar-10-26	Initiated	Rodman & Renshaw	Buy

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc Stock (ELTX) Company Profile

Compare ELTX vs VRTX, REGN, ARGX, ALNY, RVMD

Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades

Elicio Therapeutics Inc Stock (ELTX) Latest News

Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study - whbl.com

Elicio Confident In Phase III Plan Despite Phase II Miss In Pancreatic Cancer - Citeline News & Insights

Do phase II data Amplify KRAS PDAC promise for Elicio? - BioWorld News

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Yahoo Finance

Top Midday Decliners - Moomoo

ELTX Maintained by HC Wainwright & Co. -- Price Target Raised to $23 - GuruFocus

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Elicio Therapeutics Pancreatic Cancer Study Disappoints - Benzinga

ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc. - GlobeNewswire

Elicio nosedives on phase 2 data for pancreatic cancer asset (ELTX:NASDAQ) - Seeking Alpha

Elicio crashes on Phase II miss for cancer vaccine, pins hopes on post-hoc signal - FirstWord PHARMA

Elicio Therapeutics reports Phase 2 AMPLIFY-7P results - grafa.com

Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study - The Pharma Letter

Rodman & Renshaw raises Elicio Therapeutics price target to $17.50 By Investing.com - Investing.com Canada

H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy - Investing.com

Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3 - BioSpace

Why is Elicio Therapeutics stock collapsing today? By Investing.com - Investing.com Canada

Why is Elicio Therapeutics stock collapsing today? - Investing.com

Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal - marketscreener.com

Elicio Therapeutics Reports Phase 2 AMPLIFY-7P Results and Refines Phase 3 Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer – Minichart - Minichart

Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan - TipRanks

Elicio’s pancreatic cancer trial misses primary endpoint By Investing.com - Investing.com South Africa

Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX) - Yahoo Finance

Elicio’s pancreatic cancer trial misses primary endpoint - Investing.com UK

Elicio (Nasdaq: ELTX) Phase 2 ELI-002 refocuses on R0 patients - Stock Titan

Elicio Therapeutics price target raised to $23 from $17 at H.C. Wainwright - TipRanks

Elicio Therapeutics stock tumbles after trial misses endpoint By Investing.com - Investing.com South Africa

Elicio Therapeutics stock tumbles after trial misses endpoint - Investing.com

Elicio Therapeutics Reports Results From Phase 2 AMPLIFY-7P Study And Outlines Refined Phase 3 Development Strategy For ELI-002 7P In Adjuvant Pancreatic Cancer - TradingView

Pancreatic cancer trial finds DFS gain in surgery patients, Phase 3 planned - Stock Titan

Elicio Therapeutics Price Target Announced at $27.00/Share by B. Riley Securities - Moomoo

(ELTX) Risk Channels and Responsive Allocation - Stock Traders Daily

B. Riley Initiates Elicio Therapeutics at Buy With $27 Price Target - marketscreener.com

Elicio Therapeutics (ELTX) Falls 4.8% as Biotech Volatility Persists — Key Support in FocusOn Balance Volume - newsline.com

ELTX Stock Price, Quote & Chart | ELICIO THERAPEUTICS INC (NASDAQ:ELTX) - ChartMill

Elicio Therapeutics Announces Publication in Peer-Reviewed - GlobeNewswire

Elicio cancer immunotherapy triggers months-long immune memory in animals - Stock Titan

(ELTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

ELTX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $17 - GuruFocus

H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $17 - Moomoo

Elicio Therapeutics (ELTX) Holds Near Resistance as Therapeutic Pipeline Momentum BuildsAD Line Divergence - newsline.com

Elicio Therapeutics (ELTX) Climbs +8.72% — Resistance at $10.47 in Focus 2026-05-20Leveraged ETF Flow - The Legal Advocate

Elicio Therapeutics (ELTX) Q1 2026 Earnings Miss: EPS $-0.65 vs $-0.47 ExpectedEPS Consistency Score - The Legal Advocate

Liquidity Mapping Around (ELTX) Price Events - Stock Traders Daily

MIT: Big strides in cancer detection and treatment from the tiniest technologies - marketscreener.com

TradingKey - TradingKey

Elicio Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo

JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout - ChartMill

Elicio Therapeutics, Inc. 1Q 2026: Net income $(11.8M), EPS $(0.65) — 10-Q Summary - TradingView

Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times

Elicio Therapeutics Inc Stock (ELTX) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to ELTX